Study finds JAK inhibitors and tocilizumab effective in VEXAS syndrome
New research at ACR Convergence 2023, the American College of Rheumatology's (ACR) annual meeting, found that JAK inhibitors (JAKi) and tocilizumab elicited better response rates in VEXAS syndrome compared to other targeted ...
Nov 7, 2023
0
1